Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598479 | 1.00 | CXCR2 (0.32) | CXCR2DRD2HTR1DDRD3 | |
| SCHEMBL13933933 | 0.87 | ALDH1A1 (0.33) | CXCR2DRD2HTR1DDRD3 | |
| SCHEMBL4548487 | 0.79 | DRD2 (0.32) | DRD2HTR1DDRD3 | |
| SCHEMBL18587016 | 0.79 | — | — | |
| SCHEMBL17395607 | 0.77 | DRD2 (0.32) | DRD2HTR1DDRD3 | |
| SCHEMBL4548474 | 0.76 | DRD2 (0.35) | DRD2HTR1DDRD3 | |
| SCHEMBL502662 | 0.76 | SLC6A3 (0.37) | CXCR2 | |
| SCHEMBL4548472 | 0.76 | SLC6A3 (0.39) | CXCR2 | |
| SCHEMBL18617912 | 0.75 | NR1H2 (0.34) | — | |
| SCHEMBL29450323 | 0.75 | NR1H2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011035019-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7442812-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442812-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442812-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1626974-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1626974-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1626974-A2 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004094400-A2 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | MCHR1, MCHR2, MC1R | CXCR2 702/4885DRD2 472/4885HTR1D 66/4885 |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | GPER1, ESR2, ESR1 | CXCR2 1883/4885DRD2 1388/4885HTR1D 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.